ELISA Kit for Angiotensin I Converting Enzyme 2 (ACE2)

15.6-1, 000pg/mL

The minimum detectable dose of this kit is typically less than 6.2pg/mL

3h

This assay has high sensitivity and excellent specificity for detection of Angiotensin I Converting Enzyme 2 (ACE2).
No significant cross-reactivity or interference between Angiotensin I Converting Enzyme 2 (ACE2) and analogues was observed.

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Angiotensin I Converting Enzyme 2 (ACE2). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Angiotensin I Converting Enzyme 2 (ACE2). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Angiotensin I Converting Enzyme 2 (ACE2), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Angiotensin I Converting Enzyme 2 (ACE2) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

Plasma Levels of Angiotensin-Converting Enzymes 1 and 2 and AGTR2 (T1247G and A5235G) Gene Polymorphisms Are Associated to Breast Cancer Progression.; Angiotensin converting enzymes in patients with acute respiratory distress syndrome; Application of a new procedure for liquid chromatography/mass spectrometry profiling of plasma amino acid-related metabolites and untargeted shotgun proteomics to identify mechanisms and biomarkers of calcific aortic stenosis; Relationship between genetic variants of ACE2 gene and circulating levels of ACE2 and its metabolites.; Impact of angiotensin-converting enzyme 2 levels on postoperative pneumonia after esophagectomy; Angiotensin-converting enzymes in acute respiratory distress syndrome; AVE 0991 Attenuates Pyroptosis and Liver Damage after Heatstroke by Inhibiting the ROS-NLRP3 Inflammatory Signalling Pathway; Relationship between circulating levels of angiotensin-converting enzyme 2-angiotensin-(1–7)-MAS axis and coronary heart disease;